The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib.
Michel Zwaan
Consultant or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb
Linda C. Stork
No relevant relationships to disclose
Yves Bertrand
No relevant relationships to disclose
Lia Gore
No relevant relationships to disclose
Nobuko Hijiya
Consultant or Advisory Role - Genzyme
Research Funding - Bristol-Myers Squibb; Novartis
Carmino De Souza
Research Funding - University of Campinas-Brazil
Maria Lucia de Martino Lee
Research Funding - Bristol-Myers Squibb
M. Brigid Bradley-Garelik
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Pamela Kearns
No relevant relationships to disclose